ELTX
Elicio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.41
−3.60%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +23.2%
- EBIT
- +15.1%
- EPS
- +47.7%
- Free cash flow
- -7.3%
- Operating cash flow
- -7.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +2.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- +25.8%
- EBIT
- +16.2%
- Net income
- +23.8%
- EPS
- +39.3%
- Free cash flow
- +0.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026